120 related articles for article (PubMed ID: 31325530)
1. Humanized anti-CD271 monoclonal antibody exerts an anti-tumor effect by depleting cancer stem cells.
Morita S; Mochizuki M; Wada K; Shibuya R; Nakamura M; Yamaguchi K; Yamazaki T; Imai T; Asada Y; Matsuura K; Sugamura K; Katori Y; Satoh K; Tamai K
Cancer Lett; 2019 Oct; 461():144-152. PubMed ID: 31325530
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a Monoclonal Antibody That Recognizes Cysteine-Rich Domain 1 of Human CD271.
Morita S; Mochizuki M; Shibuya-Takahashi R; Nakamura-Shima M; Yamazaki T; Imai T; Asada Y; Matsuura K; Kawamura S; Yamaguchi K; Yasuda J; Sugamura K; Katori Y; Satoh K; Tamai K
Monoclon Antib Immunodiagn Immunother; 2020 Feb; 39(1):6-11. PubMed ID: 32069133
[TBL] [Abstract][Full Text] [Related]
3. CD271 defines a stem cell-like population in hypopharyngeal cancer.
Imai T; Tamai K; Oizumi S; Oyama K; Yamaguchi K; Sato I; Satoh K; Matsuura K; Saijo S; Sugamura K; Tanaka N
PLoS One; 2013; 8(4):e62002. PubMed ID: 23626764
[TBL] [Abstract][Full Text] [Related]
4. CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
Boyle SE; Fedele CG; Corbin V; Wybacz E; Szeto P; Lewin J; Young RJ; Wong A; Fuller R; Spillane J; Speakman D; Donahoe S; Pohl M; Gyorki D; Henderson MA; Johnstone RW; Papenfuss AT; Shackleton M
Cancer Res; 2016 Jul; 76(13):3965-77. PubMed ID: 27325642
[TBL] [Abstract][Full Text] [Related]
5. Cuprous oxide nanoparticle-inhibited melanoma progress by targeting melanoma stem cells.
Yu B; Wang Y; Yu X; Zhang H; Zhu J; Wang C; Chen F; Liu C; Wang J; Zhu H
Int J Nanomedicine; 2017; 12():2553-2567. PubMed ID: 28435246
[TBL] [Abstract][Full Text] [Related]
6. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth.
Civenni G; Walter A; Kobert N; Mihic-Probst D; Zipser M; Belloni B; Seifert B; Moch H; Dummer R; van den Broek M; Sommer L
Cancer Res; 2011 Apr; 71(8):3098-109. PubMed ID: 21393506
[TBL] [Abstract][Full Text] [Related]
7. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells.
Redmer T; Welte Y; Behrens D; Fichtner I; Przybilla D; Wruck W; Yaspo ML; Lehrach H; Schäfer R; Regenbrecht CR
PLoS One; 2014; 9(5):e92596. PubMed ID: 24799129
[TBL] [Abstract][Full Text] [Related]
8. Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression.
Saltari A; Dzung A; Quadri M; Tiso N; Facchinello N; Hernández-Barranco A; Garcia-Silva S; Nogués L; Stoffel CI; Cheng PF; Turko P; Eichhoff OM; Truzzi F; Marconi A; Pincelli C; Peinado H; Dummer R; Levesque MP
Cancer Res; 2021 Dec; 81(23):6044-6057. PubMed ID: 34645608
[TBL] [Abstract][Full Text] [Related]
9. CD271 regulates the proliferation and motility of hypopharyngeal cancer cells.
Mochizuki M; Tamai K; Imai T; Sugawara S; Ogama N; Nakamura M; Matsuura K; Yamaguchi K; Satoh K; Sato I; Motohashi H; Sugamura K; Tanaka N
Sci Rep; 2016 Jul; 6():30707. PubMed ID: 27469492
[TBL] [Abstract][Full Text] [Related]
10. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
11. CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma.
Murillo-Sauca O; Chung MK; Shin JH; Karamboulas C; Kwok S; Jung YH; Oakley R; Tysome JR; Farnebo LO; Kaplan MJ; Sirjani D; Divi V; Holsinger FC; Tomeh C; Nichols A; Le QT; Colevas AD; Kong CS; Uppaluri R; Lewis JS; Ailles LE; Sunwoo JB
Oncotarget; 2014 Aug; 5(16):6854-66. PubMed ID: 25149537
[TBL] [Abstract][Full Text] [Related]
12. CD271 is a negative prognostic factor and essential for cell proliferation in lung squamous cell carcinoma.
Mochizuki M; Nakamura M; Sibuya R; Okazaki T; Abe J; Nakagawa T; Takahashi S; Yamazaki T; Imai T; Takano A; Ito H; Yokose T; Miyagi Y; Daigo Y; Sato I; Satoh K; Sugamura K; Yamaguchi K; Tamai K
Lab Invest; 2019 Sep; 99(9):1349-1362. PubMed ID: 31019292
[TBL] [Abstract][Full Text] [Related]
13. CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens.
Furuta J; Inozume T; Harada K; Shimada S
J Invest Dermatol; 2014 May; 134(5):1369-1377. PubMed ID: 24226422
[TBL] [Abstract][Full Text] [Related]
14. A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells.
Orienti I; Salvati V; Sette G; Zucchetti M; Bongiorno-Borbone L; Peschiaroli A; Zolla L; Francescangeli F; Ferrari M; Matteo C; Bello E; Di Virgilio A; Falchi M; De Angelis ML; Baiocchi M; Melino G; De Maria R; Zeuner A; Eramo A
J Exp Clin Cancer Res; 2019 Aug; 38(1):373. PubMed ID: 31439019
[TBL] [Abstract][Full Text] [Related]
15. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.
Boiko AD; Razorenova OV; van de Rijn M; Swetter SM; Johnson DL; Ly DP; Butler PD; Yang GP; Joshua B; Kaplan MJ; Longaker MT; Weissman IL
Nature; 2010 Jul; 466(7302):133-7. PubMed ID: 20596026
[TBL] [Abstract][Full Text] [Related]
16. low neurotrophin receptor CD271 regulates phenotype switching in melanoma.
Restivo G; Diener J; Cheng PF; Kiowski G; Bonalli M; Biedermann T; Reichmann E; Levesque MP; Dummer R; Sommer L
Nat Commun; 2017 Dec; 8(1):1988. PubMed ID: 29215016
[TBL] [Abstract][Full Text] [Related]
17. CD271 antibody-functionalized HGNs for targeted photothermal therapy of osteosarcoma stem cells.
Tian J; Gu Y; Li Y; Liu T
Nanotechnology; 2020 Jul; 31(30):305707. PubMed ID: 32235073
[TBL] [Abstract][Full Text] [Related]
18. A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death.
Chen L; Qiu Y; Hao Z; Cai J; Zhang S; Liu Y; Zheng D
IUBMB Life; 2017 Sep; 69(9):735-744. PubMed ID: 28748573
[TBL] [Abstract][Full Text] [Related]
19. RELA is required for CD271 expression and stem-like characteristics in hypopharyngeal cancer.
Nakazato A; Mochizuki M; Shibuya-Takahashi R; Fujimori H; Fujii K; Saijoh S; Morita S; Yamazaki T; Imai T; Sato I; Satoh K; Yamaguchi K; Sugamura K; Yasuda J; Matsuura K; Shojaku H; Asada Y; Tamai K
Sci Rep; 2022 Oct; 12(1):17751. PubMed ID: 36273237
[TBL] [Abstract][Full Text] [Related]
20. Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer.
Hu Z; Xu J; Cheng J; McMichael E; Yu L; Carson WE
Oncotarget; 2017 Jan; 8(1):1481-1494. PubMed ID: 27903969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
